Search Results - "Minton, Susan E"

Randomized Trial Using Gonadotropin-Releasing Hormone Agonist Triptorelin for the Preservation of Ovarian Function During (Neo)Adjuvant Chemotherapy for Breast Cancer by MUNSTER, Pamela N, MOORE, Amy P, ISMAIL-KHAN, Roohi, COX, Charles E, LACEVIC, Mensura, GROSS-KING, Margaret, PING XU, CARTER, W. Bradford, MINTON, Susan E

“…Chemotherapy-induced amenorrhea is a serious concern for women undergoing cancer therapy. This prospective randomized trial evaluated the use of…”
Get full text

Evolutionary approaches to prolong progression-free survival in breast cancer by Silva, Ariosto S, Kam, Yoonseok, Khin, Zayar P, Minton, Susan E, Gillies, Robert J, Gatenby, Robert A

“…Many cancers adapt to chemotherapeutic agents by upregulating membrane efflux pumps that export drugs from the cytoplasm, but this response comes at an…”
Get full text

Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer by Minton, Susan E, Munster, Pamela N

“…The majority of women diagnosed with early-stage breast cancer have an excellent long-term prognosis, but many will undergo temporary or permanent…”
Get more information

A phase I study of indoximod in patients with advanced malignancies by Soliman, Hatem H, Minton, Susan E, Han, Hyo Sook, Ismail-Khan, Roohi, Neuger, Anthony, Khambati, Fatema, Noyes, David, Lush, Richard, Chiappori, Alberto A, Roberts, John D, Link, Charles, Vahanian, Nicholas N, Mautino, Mario, Streicher, Howard, Sullivan, Daniel M, Antonia, Scott J

“…Indoximod is an oral inhibitor of the indoleamine 2,3-dioxygenase pathway, which causes tumor-mediated immunosuppression. Primary endpoints were maximum…”
Get full text

First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors by MUNSTER, Pamela N, BRITTEN, Carolyn D, TOLCHER, Anthony W, MITA, Monica, GELMON, Karen, MINTON, Susan E, MOULDER, Stacy, SLAMON, Dennis J, FENG GUO, LETRENT, Stephen P, DENIS, Louis

“…Purpose: To test the tolerability, safety, and recommended phase II dose of CP-724,714, a reversible, highly selective, oral HER2 tyrosine kinase inhibitor in…”
Get full text

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer by DeMichele, Angela, Yee, Douglas, Berry, Donald A, Albain, Kathy S, Benz, Christopher C, Boughey, Judy, Buxton, Meredith, Chia, Stephen K, Chien, Amy J, Chui, Stephen Y, Clark, Amy, Edmiston, Kirsten, Elias, Anthony D, Forero-Torres, Andres, Haddad, Tufia C, Haley, Barbara, Haluska, Paul, Hylton, Nola M, Isaacs, Claudine, Kaplan, Henry, Korde, Larissa, Leyland-Jones, Brian, Liu, Minetta C, Melisko, Michelle, Minton, Susan E, Moulder, Stacy L, Nanda, Rita, Olopade, Olufunmilayo I, Paoloni, Melissa, Park, John W, Parker, Barbara A, Perlmutter, Jane, Petricoin, Emanuel F, Rugo, Hope, Symmans, Fraser, Tripathy, Debasish, van't Veer, Laura J, Viscusi, Rebecca K, Wallace, Anne, Wolf, Denise, Yau, Christina, Esserman, Laura J

“…The many improvements in breast cancer therapy in recent years have so lowered rates of recurrence that it is now difficult or impossible to conduct adequately…”
Get full text

Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial by Robert, Nicholas J, Saleh, Mansoor N, Paul, Devchand, Generali, Daniele, Gressot, Laurent, Copur, Mehmet S, Brufsky, Adam M, Minton, Susan E, Giguere, Jeffrey K, Smith, John W, Richards, Paul D, Gernhardt, Diana, Huang, Xin, Liau, Katherine F, Kern, Kenneth A, Davis, John

“…Abstract Introduction A multicenter, open-label phase III study was conducted to test whether sunitinib plus paclitaxel prolongs progression-free survival…”
Get full text

A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors by Amin, Manik, Minton, Susan E., LoRusso, Patricia M., Krishnamurthi, Smitha S., Pickett, Cheryl A., Lunceford, Jared, Hille, Darcy, Mauro, David, Stein, Mark N., Wang-Gillam, Andrea, Trull, Lauren, Lockhart, A. Craig

“…Summary Background MK-5108 is a potent/highly selective Aurora A kinase inhibitor. Methods A randomized Phase I study of MK-5108, administered p.o. BID Q12h on…”
Get full text

Phase I trial of gemcitabine plus trastuzumab and pertuzumab in previously treated metastatic HER2+ breast cancer by Soliman, Hatem Hussein, Khambati, Fatema, Han, Hyo S., Ismail-Khan, Roohi, Loftus, Loretta S., Minton, Susan E.

“…Abstract only…”
Get full text

Abstract P2-15-04: A phase 1/2 study of Ad.p53 DC vaccine with indoximod immunotherapy in metastatic breast cancer by Soliman, Hatem H, Minton, Susan E, Ismail-Khan, Roohi, Han, Hyo S, Vahanian, Nicholas N, Link, Charles J, Kennedy, Gene, Streicher, Howard, Sullivan, Daniel, Antonia, Scott J

“…Abstract Background: Indoleamine 2,3 dioxygenase (IDO) is a tryptophan-catabolizing enzyme that causes immunosuppression in the tumor microenvironment…”
Get full text

A phase 2 study of Ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors by Soliman, Hatem Hussein, Minton, Susan E., Ismail-Khan, Roohi, Han, Hyo S., Janssen, William, Vahanian, Nicholas N., Link, Charles J., Streicher, Howard, Sullivan, Daniel, Antonia, Scott Joseph

“…Abstract only…”
Get full text

A phase 2 study of docetaxel in combination with indoximod in metastatic breast cancer by Soliman, Hatem Hussein, Minton, Susan E., Ismail-Khan, Roohi, Han, Hyo S., Vahanian, Nicholas N., Ramsey, William Jay, Kennedy, Eugene, Link, Charles J., Sullivan, Daniel, Antonia, Scott Joseph

“…Abstract only…”
Get full text

A phase I study of 1-methyl-D-tryptophan in combination with docetaxel in metastatic solid tumors by Jackson, Erica, Minton, Susan E., Ismail-Khan, Roohi, Han, Heather, Neuger, Anthony, Antonia, Scott, Sullivan, Daniel, Soliman, Hatem Hussein

“…Abstract only TPS2620 Background: The indoleamine 2, 3 dioxygenase pathway (IDO) can create immune suppression and unresponsiveness to tumor antigens in…”
Get full text

Reply to Z. Blumenfeld and F. Tomao et al by Munster, Pamela N., Moore, Amy P., Ismail-Khan, Roohi, Cox, Charles E., Lacevic, Mensura, Gross-King, Margaret, Xu, Ping, Carter, W. Bradford, Minton, Susan E.

Get full text

An exploratory study to determine if BRCA1 and BRCA2 mutation carriers have higher risk of cardiac toxicity by Ismail-Khan, Roohi, Sajjad, Monique, Sun, Weihong, Soliman, Hatem Hussein, Han, Hyo S., Minton, Susan E., Lancaster, Johnathan M., Pal, Tuya

“…Abstract only 1585 Background: Anthracycline related cardiac toxicity (CT) is a concern in treating women with breast cancer. The prevalence of heart failure…”
Get full text

A phase I study of ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors by Soliman, Hatem Hussein, Minton, Susan E., Han, Hyo S., Ismail-Khan, Roohi, Mahipal, Amit, Janssen, William, Streicher, Howard, Vahanian, Nicholas N., Link, Charles J., Ramsey, William Jay, Antonia, Scott J., Sullivan, Daniel

“…Abstract only 3069 Background: Indeolamine 2,3 dioxygenase (IDO) is an inducible tryptophan-catabolizing enzyme that downregulates the immune system. Many…”
Get full text

A phase I study of indoximod in combination with docetaxel in metastatic solid tumors by Jackson, Erica, Dees, Elizabeth Claire, Kauh, John S., Harvey, R Donald, Neuger, Anthony, Lush, Richard, Antonia, Scott J., Minton, Susan E., Ismail-Khan, Roohi, Han, Hyo S., Vahanian, Nicholas N., Ramsey, William Jay, Link, Charles J., Streicher, Howard, Sullivan, Daniel, Soliman, Hatem Hussein

“…Abstract only 3026 Background: The indoleamine-2, 3-dioxygenase (IDO) pathway catabolizes tryptophan to create a state of immunosuppression. Indoximod…”
Get full text

Chemoprevention of breast cancer in the older patient by Minton, S E

“…Age is the most important risk factor for the development of breast cancer. The risk of breast cancer continues to increase in American women until the age of…”
Get more information

Severe Lhermitte-Duclos disease with unique germline mutation of PTEN by Sutphen, Rebecca, Diamond, Theresa M., Minton, Susan E., Peacocke, Monica, Tsou, Hui C., Root, Allen W.

“…Germline mutations in the PTEN gene have recently been identified in some individuals with Cowden disease (CD), Lhermitte‐Duclos disease (LDD), and…”
Get full text